Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Clifford S. Cho

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9577-7626; OpenAlex author ID A5088002732. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 8

  1. Solid conclusions and wild inferences about pancreatic cancer and the immune system. Co-author DOI 10.1016/j.gassur.2024.10.020↗
  2. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Da… Co-author DOI 10.1097/sla.0000000000003242↗
  3. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resec… Co-author DOI 10.1016/j.ijrobp.2019.08.057↗
  4. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic C… Co-author DOI 10.1200/jco.19.00730↗
  5. Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiolo… Co-author DOI 10.1245/s10434-017-5810-x↗
  6. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-ins… Co-author DOI 10.1007/s11605-014-2567-4↗
  7. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  8. Medically managed hypercholesterolemia and insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer. Co-author DOI 10.1007/s11605-011-1448-3↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hari Nathan · 4 shared papers, 2017–2021 · strength 0.42
  2. Theodore Steven Lawrence · 3 shared papers, 2019–2021 · strength 0.33
  3. Sivesh Kathir Kamarajah · 2 shared papers, 2017–2021 · strength 0.24
  4. Timothy L. Frankel · 2 shared papers, 2017–2021 · strength 0.24
  5. Mark M. Zalupski · 2 shared papers, 2019–2020 · strength 0.19
  6. Vaibhav Sahai · 2 shared papers, 2019–2020 · strength 0.19
  7. Kyle Clifford Cuneo · 2 shared papers, 2019–2020 · strength 0.19
  8. Filip Bednar · 1 shared paper, 2021 · strength 0.15
  9. Nguyen H. Tran · 1 shared paper, 2020 · strength 0.10
  10. Edward Jae-Hoon Kim · 1 shared paper, 2020 · strength 0.10
  11. Ravi Kiran Kaza · 1 shared paper, 2020 · strength 0.10
  12. Jiaqi Shi · 1 shared paper, 2020 · strength 0.10
  13. William R. Burns · 1 shared paper, 2017 · strength 0.09
  14. Leslie A. Parsels · 1 shared paper, 2019 · strength 0.08
  15. Jonathan Maybaum · 1 shared paper, 2019 · strength 0.08
  16. Meredith Ann Morgan · 1 shared paper, 2019 · strength 0.08
  17. David A. Kooby · 3 shared papers, 2011–2014 · strength 0.08
  18. Syed Ameen Ahmad · 3 shared papers, 2011–2014 · strength 0.08
  19. Sharon Marie Weber · 3 shared papers, 2011–2014 · strength 0.08
  20. Emily R. Winslow · 3 shared papers, 2011–2014 · strength 0.08
  21. Charles Raben Scoggins · 3 shared papers, 2011–2014 · strength 0.08
  22. Robert C.G. Martin · 3 shared papers, 2011–2014 · strength 0.08
  23. Jeffrey M. Sutton · 2 shared papers, 2014 · strength 0.06
  24. Alexander A. Parikh · 2 shared papers, 2014 · strength 0.06
  25. Daniel Erik Abbott · 2 shared papers, 2014 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.